Leiden, September 17th 2009 to-BBB, the Dutch brain drug delivery company, and MedImmune are starting a research program to evaluate to-BBB’s proprietary G-Technology™ to safely deliver drugs to the brain.
Many brain diseases cannot be treated with today’s disease modifying biologics due to the presence of the neuroprotective blood-brain barrier (BBB). to-BBB’s promising G-Technology is designed for safe brain delivery of different classes of drugs by formulating these drugs into proprietary glutathione coated liposomes. The G-Technology has shown proof of concept in different disease models for pain, viral encephalitis and brain tumors, based on which MedImmune will now evaluate the technology in its own pharmacodynamic models.
MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,100 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising candidates, MedImmune aims to be the next revolutionary force in biotechnology by delivering life-changing products, industry-leading performance, and a tireless commitment to improving patient health.
“We are looking forward to working with MedImmune” says Pieter Gaillard, CSO of to-BBB “The project will be of great value to further validate our brain delivery platform and work towards therapies for devastating brain diseases”.
About to-BBB
to-BBB is a Dutch biotechnology company in the field of enhanced drug delivery across the blood-brain barrier. The company is developing novel treatments for devastating brain disorders by combining existing drugs with its proprietary brain delivery platform. The company’s vision is that the treatment of currently unserved, devastating brain diseases will be best achieved by safely enhancing blood-to-brain delivery of drugs.
to-BBB is headquartered in The Netherlands at the Leiden Bio Science Park and established a fully owned subsidiary, to-BBB Taiwan Ltd., in Taipei, Taiwan.
